GerburgMWulfMD

Oncology • Boston, MA

Assistant Professor of Medicine, Beth Israel Deaconess Medical Center

Join to view full profile

Dr. Wulf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wulf's full profile

Already have an account?

Office
330 Brookline Ave/9th Fl
Beth Isreal Deaconess Med.Ctr.
Boston, MA 02115
Phone+1 617-667-0843
Is this information wrong?

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 1999
St Elizabeth's Medical CenterResidency, Internal Medicine, 1994 - 1997
Westfalischen Landes University Faculty of MedicineClass of 1987

Certifications & Licensure

MA State Medical License 1996 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 1, Phase 2
Trastuzumab and Vinorelbine in Advanced Breast Cancer Start of enrollment: 2010 Nov 01
Terminated
Phase 2
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
BKM120 For Triple Negative Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer Start of enrollment: 2017 Mar 30
Active, not recruiting
Phase 2
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Start of enrollment: 2017 Feb 17
Active, not recruiting
Phase 1
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Mar 22
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Reciprocal antagonism of PIN1-APC/Cgoverns mitotic protein stability and cell cycle entry.
Shizhong Ke, Fabin Dang, Lin Wang, Jia-Yun Chen, Mandar T Naik, Wenxue Li, Abhishek Thavamani, Nami Kim, Nandita M Naik, Huaxiu Sui, Wei Tang, Chenxi Qiu, Kazuhiro Koi...> ;Nature Communications. 2024 Apr 15
Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report.
Emilie Platteter, Gerburg Wulf> ;Case Reports in Oncology. 2024 Mar 1
3 citations
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier, Allison M Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom,...> ;Cancer Discovery. 2024 Feb 8
Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.
Jadhav, H., Pantelidou, C., Phan, T., Grochala, C., Mehta, A., Guerriero, J., D'Andrea, A., Patterson-Fortin, J., Wulf, G., Wolpin, B., Stanger, B., Aguirre, A., Clear...> ;Nature Communications. 2023 Dec 11
Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report.
Yujing J Heng, Kevin J Zhang, Monica G Valero, Gabrielle M Baker, Valerie J Fein-Zachary, Michael S Irwig, Gerburg M Wulf> ;Case Reports in Oncology. 2023 Sep 4
1 citations
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic/, Germli...
Felipe Batalini, Russell W Madison, Ethan S Sokol, Dexter X Jin, Kuei-Ting Chen, Brennan Decker, Dean C Pavlick, Garrett M Frampton, Gerburg M Wulf, Judy E Garber, Geo...> ;JCO Precision Oncology. 2023 Sep 1
3 citations
Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms.
Jenny M Hogstrom, Kayla A Cruz, Laura M Selfors, Madelyn N Ward, Tejas S Mehta, Naama Kanarek, Jordana Philips, Vandana Dialani, Gerburg Wulf, Laura C Collins, Jaymin ...> ;The Journal of Biological Chemistry. 2023 Aug 1
10 citations
Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.
Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita K Mehta, Jennifer L Guerriero, Gerburg M Wulf, Brian M Wolpin, Ben Z Sta...> ;Nature Communications. 2023 Mar 13
2 citations
Toker Cell Hyperplasia in the Nipple-Areolar Complex of Transmasculine Individuals.
Gabrielle M Baker, Vanessa C Bret-Mounet, Jingxiong Xu, Valerie J Fein-Zachary, Adam M Tobias, Richard A Bartlett, John G Clohessy, Ioannis S Vlachos, Erica S Massicot...> ;Modern Pathology. 2023 Jun 1
11 citations
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.
Varduhi Petrosyan, Lacey E Dobrolecki, Lillian Thistlethwaite, Alaina N Lewis, Christina Sallas, Ramakrishnan R Srinivasan, Jonathan T Lei, Vladimir Kovacevic, Predrag...> ;Iscience. 2023 Jan 20
Reciprocal inhibition of PIN1 and APC/Ccontrols timely G1/S transition and creates therapeutic vulnerability.
Shizhong Ke, Fabin Dang, Lin Wang, Jia-Yun Chen, Mandar T Naik, Abhishek Thavamani, Yansheng Liu, Wenxue Li, Nami Kim, Nandita M Naik, Huaxiu Sui, Wei Tang, Chenxi Qiu...> ;Research Square. 2023 Jan 19
11 citations
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
Lin Wang, Dan Wang, Olmo Sonzogni, Shizhong Ke, Qi Wang, Abhishek Thavamani, Felipe Batalini, Sylwia A Stopka, Michael S Regan, Steven Vandal, Shengya Tian, Jocelin Pi...> ;Cell Reports. 2022 Oct 11
8 citations
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.
Adrienne G Waks, Tanya E Keenan, Tianyu Li, Nabihah Tayob, Gerburg M Wulf, Edward T Richardson 3rd, Victoria Attaya, Leilani Anderson, Elizabeth A Mittendorf, Beth Ove...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
9 citations
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer.
Constantia Pantelidou, Heta Jadhav, Aditi Kothari, Renyan Liu, Gerburg M Wulf, Jennifer L Guerriero, Geoffrey I Shapiro> ;NPJ Breast Cancer. 2022 Sep 6
11 citations
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
Felipe Batalini, Doga C Gulhan, Victor Mao, Antuan Tran, Madeline Polak, Niya Xiong, Nabihah Tayob, Nadine M Tung, Eric P Winer, Erica L Mayer, Stian Knappskog, Per E ...> ;Clinical Cancer Research. 2022 Nov 1
AC/P surface coil to visualize metabolism and energetics in the rodent brain at 3 Tesla.
Manushka V Vaidya, Bei Zhang, DongHyun Hong, Ryan Brown, Georgios Batsios, Pavithra Viswanath, Jan Paska, Gerburg Wulf, Aaron K Grant, Sabrina M Ronen, Peder E Z Larson> ;Journal of Magnetic Resonance. 2022 Oct 1
19 citations
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C Cantley, Geoffrey I Shapiro, Viktor Adalsteinsson, Eric P Winer, Panagiotis A Konsta...> ;Clinical Cancer Research. 2022 Apr 14
2 citations
The association of infectious mononucleosis and invasive breast cancer in The Health of Women (HOW) Study.
Yujing Jan Heng, Susan Love, Jessica Clague DeHart, Joyce D Fingeroth, Gerburg M Wulf> ;Breast Cancer. 2022 Jul 1
6 citations
WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.
Takahiro Kishikawa, Hiroshi Higuchi, Limei Wang, Nivedita Panch, Valerie Maymi, Sachem Best, Samuel Lee, Genso Notoya, Alex Toker, Lydia E Matesic, Gerburg M Wulf, Wen...> ;The Journal of Clinical Investigation. 2021 Dec 15
18 citations
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Tanya Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, ...> ;Nature Communications. 2021 Sep 21
85 citations
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Kazuhiro Koikawa, Shin Kibe, Futoshi Suizu, Nobufumi Sekino, Nami Kim, Theresa D. Manz, Benika J. Pinch, Dipikaa Akshinthala, Ana Verma, Giorgio Gaglia, Yutaka Nezu, S...> ;Cell. 2021 Sep 2
10 citations
Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH-A genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR
Gopal Varma, Pankaj Seth, Patricia Coutinho de Souza, Cody Callahan, Jocelin Pinto, Manushka Vaidya, Olmo Sonzogni, Vikas P. Sukhatme, Gerburg M. Wulf, Aaron K. Grant> ;NMR in Biomedicine. 2021 Aug 1
3 citations
Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells
Heather A. Parsons, Erin R. Macrae, Hao Guo, Tianyu Li, William T. Barry, Nabihah Tayob, Gerburg M. Wulf, Steven J. Isakoff, Ian E. Krop> ;JCO Precision Oncology. 2021 May 20
18 citations
Blockade of 6-phosphogluconate dehydrogenase generates CD8+ effector T cells with enhanced anti-tumor function.
Saeed Daneshmandi, Teresa Cassel, Penghui Lin, Richard M. Higashi, Gerburg M. Wulf, Vassiliki A. Boussiotis, Teresa W.-M. Fan, Pankaj Seth> ;Cell Reports. 2021 Mar 9
14 citations
Testosterone therapy and breast histopathological features in transgender individuals.
Gabrielle M. Baker, Yaileen D Guzman-Arocho, Vanessa C. Bret-Mounet, Vanda F. Torous, Stuart J. Schnitt, Adam M. Tobias, Richard A. Bartlett, Valerie Fein-Zachary, Lau...> ;Modern Pathology. 2021 Jan 1
Join now to see all

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology